How many drugs treat Anemia of renal disease?

Drug Landscape tracks 5 marketed treatments for Anemia of renal disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/anemia-of-renal-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anemia of renal disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anemia of renal disease (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Anemia of renal disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Jesduvroq	DAPRODUSTAT	GSK	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC]	Egl nine homolog 1	2023-01-01
Aranesp	DARBEPOETIN ALFA	Amgen	Erythropoiesis-stimulating Agent [EPC]	Erythropoietin receptor	2001-01-01
Enaroy	ENARODUSTAT	Japan Tabacco		Egl nine homolog 1
Aranesp	Aranesp	University of Washington		Erythropoietin receptor
Darbepoetin	Darbepoetin	NICHD Neonatal Research Network		Erythropoietin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 1 drug in Anemia of renal disease
GSK · 1 drug in Anemia of renal disease
Japan Tabacco · 1 drug in Anemia of renal disease
NICHD Neonatal Research Network · 1 drug in Anemia of renal disease
University of Washington · 1 drug in Anemia of renal disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Anemia of renal disease:

Cite this brief

Drug Landscape (2026). Anemia of renal disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/anemia-of-renal-disease. Accessed 2026-06-10.

Anemia of renal disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing